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Abstract
Introduction Limb-sparing surgery with negative margins is possible in most soft tissue sarcoma (STS) resections and 
focuses on maximising function and minimising morbidity. Various risk factors for surgical site infections (SSIs) have been 
reported in the literature specific to sarcoma surgery. The aim of this study is to determine whether systemic inflammatory 
response prognostic scoring systems can predict post-operative SSI in patients undergoing potentially curative resection of 
STS.
Methods Patients who had a planned curative resection of a primary STS at a single centre between January 2010 and 
December 2019 with a minimum follow-up of 6 months were included. Data were extracted on patient and tumour character-
istics, and pre-operative blood results were used to calculate inflammatory prognostic scores based on published thresholds 
and correlated with risk of developing SSI or debridement procedures.
Results A total of 187 cases were included. There were 60 SSIs. On univariate analysis, there was a statistically significant 
increased risk of SSI in patients who are diabetic, increasing specimen diameter, American Society of Anaesthesiology 
(ASA) grade 3, use of endoprosthetic replacement, blood loss greater than 1 L, and junctional tumour location. Modified 
Glasgow prognostic score, C-reactive protein/albumin ratio and neutrophil–platelet score (NPS) were statistically associ-
ated with the risk of SSI. On multivariate analysis, ASA grade 3, junctional tumour location and NPS were independently 
associated with the risk of developing a SSI.
Conclusion This study supports the routine use of simple inflammation-based prognostic scores in identifying patients at 
increased risk of developing infectious complications in patients undergoing potentially curative resection of STS.
Keywords Soft tissue sarcoma · Infection · Inflammatory prognostic score · Modified Glasgow prognostic score
Introduction
The principles of management of soft tissue sarcoma (STS) 
have evolved considerably in recent years. Limb-sparing 
surgery with negative margins is possible in the major-
ity of resections and focuses on maximising function and 
minimising morbidity [1, 2]. Amputation is only required 
in approximately 10% of cases, where the involvement of 
critical anatomic structures prevents a curative wide local 
surgical resection [3]. However, limb-sparing resections 
often involve large surgical fields, and surgical site infection 
(SSI) remains an important source of post-operative morbid-
ity [4]. Wound complications including dehiscence, celluli-
tis, abscess, seromas, haematomas and wound necrosis have 
been reported to occur in 16–56% cases in the published 
literature [4, 5].
Various risk factors for surgical site infections have been 
reported in the literature specific to sarcoma surgery, and 
these can be sub-classified into surgical factors, host fac-
tors and adjunctive treatment factors [5–7]. Large tumour 
resections, particularly involving the adductor compartment 
of the thigh, use of adjuvant radiotherapy, and a variety of 
patient-specific factors including smoking, diabetes and 
obesity, have all been reported to independently affect the 
risk of SSIs [8]. Identification and knowledge of such risk 
factors is important as it allows appropriate patient counsel-
ling and can guide future research in reducing these risks. 
Recent proposals have focussed on these high risk wounds 
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and look to utilise existing technology such as negative pres-
sure wound therapy to mitigate these risk factors [9]. There 
is also evidence to support the immediate use of free-flap 
reconstruction, particularly in patients who receive neoad-
juvant radiotherapy, in an effort to substitute irradiated soft 
tissue for healthy soft tissue from the donor site, and opti-
mising the vascularisation of the resection site [10].
There has been increasing evidence over the last two dec-
ades that the host response to malignancy plays a key role in 
the prognosis and outcomes of treatment. A systemic inflam-
matory response is a proposed unifying model for this host 
interaction with the tumour, with various scoring systems 
proposed to quantify this [11–14]. These scoring systems 
rely on routine haematological and biochemical laboratory 
parameters to stratify this response, and they have been 
shown in numerous studies to correlate with survival in 
a variety of malignancies [13, 15]. More recent work has 
focussed on their use in predicting post-operative morbid-
ity, particularly in potentially curative carcinoma resections 
[16].
However, only limited data are available on the applica-
bility of systemic inflammatory response prognostic scores 
in the management of soft tissue sarcomas, which represent 
a different cellular lineage to carcinomas [17]. Emerging evi-
dence supports a correlation between the modified Glasgow 
prognostic score (mGPS) and survival in soft tissue sarcoma, 
but no studies have investigated their relationship with post-
operative SSIs in soft tissue sarcoma. Therefore, the aim of 
this study is to determine whether systemic inflammatory 
response prognostic scoring systems can independently pre-
dict post-operative surgical site infection in patients under-
going potentially curative resection of soft tissue sarcoma.
Methods
All patients who had a planned curative resection of a pri-
mary STS in the West of Scotland between the calendar 
years January 2010 and December 2019 with a minimum 
follow-up of 6 months were entered into the study. These 
patients were identified from a prospectively maintained 
database. Review of the electronic case notes was performed 
for 213 patients who met the inclusion criteria. Any patient 
with metastatic disease at presentation, a low grade tumour 
subtype (atypical lipomatous tumour/dermatofibrosarcoma 
protuberans) or incomplete data were excluded to avoid 
selection and transfer bias. As a result of access to a national 
electronic case note files, no patients were lost to follow-up.
All patients were treated surgically under the supervision 
of the two senior authors (AM and SG). Data were extracted 
on sex, age, height, weight, use of adjuvant therapy, co-
morbidities, American Society of Anaesthesiology (ASA) 
grade, intra-operative blood loss, tumour size, tumour grade, 
specimen size, location of tumour and need for immediate 
soft tissue reconstruction. We grouped tumour location into 
anatomic location but described a subset which we defined 
as junctional, which occur in the axilla, groin, popliteal fossa 
and distal medial thigh. All patients received a low-pressure 
vacuum drain in the immediate post-operative period, which 
was left in situ until drainage was less than 50 ml over a 24-h 
period. Peri-operative antibiotic prophylaxis was routinely 
continued until drain removal. Thrombo-embolic prophy-
laxis consisted of low-molecular weight heparin, which 
was maintained as inpatient therapy for all patients, and for 
4 weeks post-operatively in lower limb sarcoma surgery.
Pre-operative blood results including C-reactive protein, 
albumin, white cell count, neutrophil, lymphocyte and plate-
let count were collected. These data were used to calculate 
established inflammatory scoring systems based on validated 
thresholds as demonstrated in Table 1 [13].
Data were collected on post-operative surgical site infec-
tions (SSIs). Patients were routinely followed up at 2 weeks 
post-operatively at the sarcoma clinic, then at regular inter-
vals thereafter until the wound is satisfactory. If patients 
underwent soft tissue reconstruction, then the immedi-
ate post-operative follow-up was by the onco-plastic team 
weekly for the first 4 weeks. If post-operative radiotherapy 
was recommended, this was instituted once the wound was 
deemed satisfactory by the surgical team, and standard treat-
ment was to commence this at 6 weeks post-operatively. 
We defined a post-operative SSI as a surgical site requiring 
treatment with antibiotic therapy or an infective complica-
tion that required surgical intervention such as debridement 
and washout of the surgical site. No ethical approval was 
required for this study.
Statistics
Variables were groups by standard binary or categorical 
thresholds. Univariate survival analysis was performed using 
a Cox proportional hazards model taking into account time 
to surgical site infection. Kaplan–Meir analysis using log-
rank test was used to graphically demonstrate significance. 
A p-value of < 0.05 was considered statistically significant. 
Multivariate analysis was performed using a Cox propor-
tional hazards model with a stepwise backward procedure 
to derive a final model of the variables that had a significant 
independent relationship with post-operative surgical site 
complications.
Inter-relationships between variables were assessed using 
contingency table analysis with the Chi square test for trend 
as appropriate. For variables with few observations, Fisher 
exact test was used. Analysis was performed using SPSS 
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software (version 26.0.0. SPSS Inc, Chicago, IL, USA) or 
GraphPad Prism (version 6, San Diego, CA, USA).
Results
Between January 2010 and December 2019, there were 
187 cases eligible for analysis. A summary of the clinico-
pathological characteristics of the patients is presented in 
Table 2. There were 60 surgical site infections; 21 of these 
were treated with antibiotic therapy, and 39 patients required 
an additional surgical procedure. Median time to diagnosis 
of any surgical site infection was 22 days (interquartile range 
14–40 days), and median time to surgical intervention was 
21 days (interquartile range 16–34 days). There were 21 dis-
tinct subtypes of soft tissue sarcomas within our group, and 
these are summarised in Table 3.
Table 1  Systemic inflammation-
based prognostic ratios and 
scores
NLR Neutrophil–lymphocyte ratio; NLS neutrophil–lymphocyte score; PLR platelet–lymphocyte ratio; PLS 
platelet–lymphocyte score; LMR lymphocyte–monocyte ratio; LMS lymphocyte–monocyte score; NPS neu-
trophil–platelet score; CAR C-reactive protein–albumin ratio; mGPS modified Glasgow prognostic score
Ratio/score Ratio/score
NLR
Neutrophil count/lymphocyte count  ≤ 3
Neutrophil count/lymphocyte count 3–5
Neutrophil count/lymphocyte count  > 5
NLS
Neutrophil count ≤ 7.5 ×  109/l and lymphocyte count ≥ 1.5 ×  109/l 0
Neutrophil count > 7.5 ×  109/l and lymphocyte count ≥ 1.5 ×  109/l 1
Neutrophil count ≤ 7.5 ×  109/l and lymphocyte count < 1.5 ×  109/l 1
Neutrophil count > 7.5 ×  109/l and lymphocyte count < 1.5 ×  109/l 2
PLR
Platelet count/lymphocyte count  ≤ 150
Platelet count/lymphocyte count  > 150
PLS
Platelet count ≤ 400 ×  109/l and lymphocyte count ≥ 1.5 ×  109/l 0
Platelet count > 400 ×  109/l and lymphocyte count ≥ 1.5 ×  109/l 1
Platelet count ≤ 400 ×  109/l and lymphocyte count < 1.5 ×  109/l 1
Platelet count > 400 ×  109/l and lymphocyte count < 1.5 ×  109/l 2
LMR
Lymphocyte count/monocyte count  ≥ 2.40
Lymphocyte count/monocyte count  < 2.40
LMS
Lymphocyte count ≥ 1.5 ×  109/l and monocyte count ≤ 0.8 ×  109/l 0
Lymphocyte count ≥ 1.5 ×  109/l and monocyte count ≤ 0.8 ×  109/l 1
Lymphocyte count < 1.5 ×  109/l and monocyte count > 0.8 ×  109/l 1
Lymphocyte count < 1.5 ×  109/l and monocyte count > 0.8 ×  109/l 2
NPS
Neutrophil count ≤ 7.5 ×  109/l and platelet count < 400 ×  109/l 0
Neutrophil count > 7.5 ×  109/l and platelet count < 400 ×  109/l 1
Neutrophil count ≤ 7.5 ×  109/l and platelet count > 400 ×  109/l 1
Neutrophil count > 7.5 ×  109/l and platelet count > 400 ×  109/l 2
CAR 
C-reactive protein/albumin  ≤ 0.22
C-reactive protein/albumin  > 0.22
mGPS
C-reactive protein ≤ 10 mg/l and albumin ≥ 35 g/l 0
C-reactive protein > 10 mg/l and albumin ≥ 35 g/l 1
C-reactive protein > 10 mg/l and albumin < 35 g/l 2
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Table 2  Variable distribution and univariate Cox regression analysis
Variable Total No complication Complication p-value Hazard ratio (95% CI)
Number of patients 187 127 60 –
Sex 0.938
  Male 90 61 29
 Female 97 66 31
Mean age in years (Range) 59.0 (19–93) 59 (20–91) 59 (19–93) 0.960
Mean BMI (range) 28.3 (17.7–68.5) 27.9 (17.7–68.5) 29.1 (19.4–55.5) 0.219
Trojani tumour grade 0.175
  Grade 1 16 13 3
 Grade 2 49 35 14
 Grade 3 122 79 43
Mean tumour diameter in cm (range) 9.42 ( 0.5–31.0) 9.0 (0.5 – 31.0) 10.3 (1.3–27.5) 0.206
Mean specimen diameter in cm (range) 16.1 (2.0–39.0) 14.9 (2.0–39.0) 18.7 (3.0–34.0) 0.003 1.06 (1.02–1.09)
Tumour site 4.69 (1.11–19.76)
 Trunk 15 13 2 –
 Upper limb 35 29 6 0.73
 Lower limb 86 60 26 0.218
 Junctional 51 25 26 0.035
Adjuvant radiotherapy
 None 57 42 15 –
 Adjuvant 98 66 32 0.615
 Neoadjuvant 32 19 13 0.217
Wound closure 0.486
 Primary 95 67 28
 Soft tissue reconstruction 92 60 32
ASA grade
 II 143 105 38 – 2.42 (1.42–4.12)
 III 39 18 21 0.001
0.812 IV 5 4 1
Diabetes mellitus 0.045 1.95 (1.01–3.76)
 Yes 165 116 11
 No 22 11 49
Hypertension 0.147
 Yes 118 15 8
 No 68 112 51
Hypercholesterolaemia 163 15 8 0.819
 Yes 23 112 51
 No
Smoker 0.744
 Active 30 20 10
 Non-active 157 107 50
Surgery type 0.646
 Ablative 26 19 7
 Limb sparing 161 108 53
Bone reconstruction 0.028 2.43 (1.10–5.35)
 Nil 177 124 53
 Endoprosthesis 10 3 7
Blood loss 0.022 2.22 (1.12–4.38)
  < 1 Litre 170 120 50
  > 1 Litre 17 7 10
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Univariate analysis determined that there was a statisti-
cally significant increased risk of SSI in patients who are 
diabetic (50% versus 29.7%, p = 0.045) and patients with 
an ASA grade 3 (53.8% versus 26.6% ASA 2 patients, 
p = 0.001). There was no significant association between 
other patient related risk factors such as sex, age, smok-
ing status, Body Mass Index (BMI), hypertension or 
hypercholesterolaemia.
With regard to pathological characteristics, the mean 
tumour diameter was 9.42  cm and the mean specimen 
diameter was 16.1 cm. The majority of tumours were Tro-
jani grade 3 (65.2%). There was a statistically significant 
6% increased risk of complications per centimetre increase 
in the maximum measured specimen diameter (p = 0.003). 
There was no association between risk of complication and 
maximum measured tumour diameter or Trojani tumour 
grade.
Surgical factors associated with increased risk of post-
operative SSI include intra-operative blood loss greater 
than 1 L (58.8% versus 29.4%, p = 0.022), junctional loca-
tion of tumour (51% versus 17.1% in upper limb, p = 0.035) 
and implantation of an endoprosthesis (70% versus 29.9%, 
p = 0.028). There was no statistically significant association 
with need for primary amputation, neoadjuvant or adjuvant 
radiotherapy or type of wound closure.
We examined the association of SSI with various pre-
viously described systemic inflammatory scoring systems. 
There was a statistically significant association between 
the modified Glasgow prognostic scoring system (mGPS), 
C-reactive protein-to-albumin ratio (CAR), neutrophil–plate-
let score (NPS) and risk of developing a surgical site infec-
tion (all p < 0.05). There was no statistically significant 
association on univariate analysis with the neutrophil–lym-
phocyte ratio (NLR), neutrophil–lymphocyte score (NLS), 
platelet–lymphocyte ratio (NLR) and platelet–lymphocyte 
score (PLS) and the risk of developing post-operative SSI.
On multivariate analysis, we identified three independent 
risk factors for developing a post-operative SSI (Table 4). 
Table 2  (continued)
Variable Total No complication Complication p-value Hazard ratio (95% CI)
mGPS 0.019 1.41 (1.06–1.88)
 0 108 81 27
 1 38 24 14




 0 100 74 26
 1 84 50 34
NLR 0.182
 0 89 65 24
 1 58 37 12
 2 38 23 15
NLS 0.230
 0 99 70 29
 1 78 51 27
 2 8 4 4
PLR 0.103
 0 60 46 14
 1 125 79 46
PLS 0.131
 0 94 67 27
 1 84 56 28
 2 7 2 5
NPS 0.004 1.73 (1.19–2.52)
 0 148 107 41
 1 28 15 13
 2 9 3 6
BMI = body mass index, CI = confidence interval
Bold represents statistically significant finding
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The NPS was significantly and independently associated 
with an increased risk of SSI, with a hazard ratio of 1.64 
(95% CI 1.11–2.40) per level increase in value (p = 0.012). 
Additionally, ASA grade 3 was associated with a hazard 
ratio of 2.24 (1.30–3.85) when compared to ASA grade 
2 (p = 0.004), and a tumour located in a junctional area 
was associated with a hazard ratio of 3.74 (1.53–9.12) for 
developing a SSI (p = 0.004). Figure 1 demonstrates the 
Kaplan–Meir survival curves for these factors.
We examined associations between the variables col-
lected and the three systemic inflammatory scoring systems 
that were statistically significant on univariate analysis, 
namely mGPS, CAR and NPS (Table 5). There was a sta-
tistically significant association of all three scoring sys-
tems with increasing age, higher-grade tumour, increased 
tumour diameter size and specimen size, and increased 
intra-operative blood loss. NPS and mGPS were both sta-
tistically significantly associated with increased ASA score. 
Patients with an elevated mGPS and CAR were more likely 
to undergo ablative surgery. Patients with an elevated CAR 
were statistically significantly associated with an increased 
rate of soft tissue reconstruction. 
Discussion
This study has demonstrated that the pre-operative systemic 
inflammatory prognostic scores, namely the modified Glas-
gow prognostic score, the C-reactive protein-to-albumin 
ratio and the neutrophil–platelet score, were all statisti-
cally significant prognostic factors for development of SSI 
in patients undergoing potentially curative resection of soft 
tissue sarcoma, with the latter also being an independent risk 
factor on multivariate analysis.
Post-operative SSI is relatively common in patients 
undergoing resection of soft tissue sarcoma, associated with 
increased hospital stay, treatment costs and may result in 
delays to adjuvant radiotherapy. Therefore, identifying at-
risk patients is key to informed consent, but can also allow 
targeted interventions to mitigate these risks. The results of 
this study suggest that patients with an elevated NPS, ASA 
grade 3 or tumours resected from a junctional location may 
benefit from such interventions. Incisional negative pressure 
wound therapy has been utilised in orthopaedic and non-
orthopaedic surgical scenarios, both routinely and targeted 
in at-risk wounds and has been shown to minimise the risk 
of post-operative wound complications, with an ongoing 
randomised control trial investigating its utility in soft tis-
sue sarcoma surgery [18–21]. In addition, it has been shown 
that the use of soft tissue reconstruction can minimise the 
risk of surgical site infections in soft tissue sarcoma surgery, 
particularly patients who undergo neoadjuvant radiotherapy 
[22, 23]. Whilst our study found no association between the 
Table 3  Tumour histology types included in study
NOS: not otherwise specified
Tumour type n
Undifferentiated sarcoma NOS 34
Undifferentiated pleomorphic sarcoma 25
Myxoid liposarcoma 24











Pleomorphic hyalinising angiectatic 1
Epithelioid sarcoma 1
Small cell neuroendocrine 1
Clear cell sarcoma 1
Fibromyxoid sarcoma 1
Myxoinflammatory fibroblastic sarcoma 1
Round cell sarcoma 1
Table 4  Statistical association between variables included in study 
and systemic inflammatory scoring systems significant on univariate 
analysis
Bold represents statistically significant finding
Variable NPS CAR mGPS
Sex 0.333 0.685 0.584
Age 0.034  < 0.001 0.002
BMI 0.710 0.083 0.106
Trojani tumour grade 0.016  < 0.001  < 0.001
Tumour diameter 0.001  < 0.001  < 0.001
Specimen diameter 0.004  < 0.001  < 0.001
Tumour site 0.199 0.313 0.245
Adjuvant radiotherapy 0.103 0.014 0.054
Wound closure 0.478 0.008 0.054
ASA grade 0.041 0.399 0.002
Diabetes mellitus 0.901 0.663 0.818
Hypertension 0.572 0.392 0.179
Hypercholesterolaemia 0.079 0.519 0.788
Smoker 0.916 0.060 0.352
Surgery type 0.215 0.029 0.027
Bone reconstruction 0.161 0.516 0.393
Blood loss 0.001 0.040  < 0.001
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use soft tissue reconstruction and risk of complications, it is 
likely that the retrospective nature of this study resulted in a 
treatment selection bias. Indeed, we noted a higher than pub-
lished rate of soft tissue reconstruction in our study cohort 
(49.1%), and this likely represents our evolution in practice 
with time to a more aggressive surgical approach using soft 
tissue reconstruction.
The basis of the independent relationship between an 
elevated systemic inflammatory response pre-operatively 
and post-operative infections in patients with primary 
operable soft tissue sarcoma is not clear. Whilst both the 
cell-mediated immune response and humoral immune 
response are associated with post-operative SSI, only the 
former was independently associated with complications. 
This is in contrast with disease-free survival in soft tis-
sue sarcoma, which is more closely associated with the 
humoral immune response as measured by the mGPS [17]. 
It is also interesting to note that whilst the tumour size 
and grade were associated with an elevated mGPS, CAR 
and NPS, they were not associated with an increased risk 
of complications. We therefore hypothesise that whilst 
the tumour elicits a significant systemic inflammatory 
response in the host, it is this dysfunctional response that 
predisposes to the increased risk of SSI, and that these 
biomarkers measure the dysfunctional response rather than 
act as surrogates to tumour aggressiveness in the aetiology 
and prediction of surgical site infections.
Systemic inflammation and nutritional status are clearly 
inter-linked. Inflammation impairs nutritional status by 
reducing food intake and impairing micronutrient absorp-
tion, and malnutrition increases the risk and severity of 
inflammation [24, 25]. Whilst BMI was not associated with 
the risk of SSI or with an increased systemic inflammatory 
prognostic scores, it is well recognised that absolute BMI is 
a poor marker of nutritional status in cancer [26, 27]. Several 
studies have identified a link between inflammatory prognos-
tic scores, skeletal muscle mass and cancer cachexia, and 
poor nutritional status has been demonstrated to increase 
the risk of peri-operative complications including surgical 
site infections [28–30]. Further research aimed at identify-
ing a link between inflammatory prognostic scores, cancer 
cachexia and surgical site infection in soft tissue sarcoma 
can provide easy identification of these patients and poten-
tiate a pathway for intervening in this group to potentially 
reduce their risk of SSI.
It is interesting to note that the mean specimen diameter 
was significantly associated with risk of post-operative 
surgical site infections, but that tumour diameter is not. 
To the best of our knowledge, this is the first paper to 
distinguish between tumour size and specimen size in the 
Fig. 1  Kaplan–Meir survival graph demonstrating risk of surgical site infection with a) NPS, b) mGPS, c) tumour location and d) ASA grade
Table 5  Variables determined to predict surgical site infection on 
multivariate analysis
Variable P-value Hazard ratio (95% CI)
ASA grade 3 0.004 2.24 (1.29–3.88)
Neutrophil–platelet score 0.012 1.64 (1.11–2.40)
Junctional tumour location 0.004 3.74 (1.53–9.12)
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same cohort. This supports the hypothesis that it is the 
residual dead space created by resection of larger tumours 
which predisposes to development of seromas and hema-
tomas, as well as subsequent infection [4]. The significant 
association between increased blood loss and risk of post-
operative SSI is likely driven by a similar mechanism. It 
has also been suggested that intra-operative blood transfu-
sion may act synergistically with surgical stress to induce 
immunosuppression, and increased blood loss is likely to 
be associated with higher risk of intra-operative blood 
transfusion [31, 32].
Anatomic location of tumour is also a significant 
prognostic indicator of SSI [2, 8, 33]. Prior studies have 
focussed on anatomic divisions, but we hypothesised that 
grouping patients based on this feature alone can result in 
a dilutional effect. We have shown that these at risk areas, 
namely the medial thigh, popliteal fossa, groin and axilla 
are more appropriately grouped and are an independent 
risk factors for SSI. It has been postulated that certain 
sites are more at risk of SSI due to en bloc resection of 
venous and lymphatic vessels, which result in seroma and 
subsequent infection [8, 33]. In addition, we propose two 
other features that may account for the high risk nature of 
these areas. There is likely a mechanical shear and ten-
sile effect on the soft tissue in these areas, which often 
fall in junctional zones. In addition, these areas show a 
high concentration of gram negative or anaerobic flora, 
which may represent more opportunistic and more virulent 
micro-organisms [34].
We recognise that this is a heterogenous group of 
patients, in terms of both tumour aetiology and patient 
characteristics. This represents a limitation of our paper 
but is reflective of standard sarcoma surgeon’s practice. 
In addition, the heterogenous nature represents a further 
demand for a simplified, unified method of appropriately 
stratifying risk of surgical site infection in this varied 
cohort of patients, presentations and management types.
In summary, this study supports the routine use of 
simple inflammation-based prognostic scores in identi-
fying patients at increased risk of developing infectious 
complications in patients undergoing potentially curative 
resection of soft tissue sarcoma. However, it remains to be 
determined whether the pre-operative systemic inflamma-
tory response may be moderated and whether such moder-
ation may reduce post-operative infectious complications, 
and further prospective work is required to clarify whether 
interventions can be targeted in this at risk group to mini-
mise these complications.
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